Overview

Reducing harmful use of alcohol is a public health imperative, accordingly to the World Health Organization. With over 26% of adult population being heavy drinkers, central countries face a rising epidemic of related pathologies such as Liver Disease and Steatohepatitis, causing an unsustainable trillion-dollar burden. Galea pipeline is formed by a novel class of molecules offering a uniquely comprehensive therapy to address the multifactorial pathogenesis of these conditions, with activity in the liver and Peripheral Nervous System.